Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2723-2733

  Yu, Ke Da ^a   Zhu, Rui ^b   Zhan, Ming ^b   Rodriguez, Angel A ^c   Yang, Wei ^d   Wong, Stephen ^b   Makris, Andreas ^f   Lehmann, Brian D ^e   Chen, Xi ^e   Mayer, Ingrid ^e   Pietenpol, Jennifer A ^e   Shao, Zhi Ming ^a   Symmans, W Fraser ^d   Chang, Jenny C ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e VANDERBILT INGRAM CANCER CENTER   (United States)

^f MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTHRACYCLINE DERIVATIVE; CELL MARKER; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 28; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; WNT11 PROTEIN; CYTOKERATIN 16; ESTROGEN RECEPTOR BETA; GATA3 PROTEIN, HUMAN; GBX2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; KRT16 PROTEIN, HUMAN; MMP28 PROTEIN, HUMAN; WNT PROTEIN; WNT11 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURGERY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; VALIDATION PROCESS; ADJUVANT THERAPY; DNA MICROARRAY; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PATHOLOGY; PROCEDURES; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR BETA; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; KERATIN-16; MATRIX METALLOPROTEINASES, SECRETED; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTORS, ANDROGEN; TRIPLE NEGATIVE BREAST NEOPLASMS; WNT PROTEINS;

EID: 84878069977     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2986     Document Type: Article

References (36)

1. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012;30:1879-87.
2. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7:e1000279.
3. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
4. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-9.
5. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
6. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
7. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011;305: 1873-81.
8. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25:4414-22.
9. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-44.
10. Chevallier B, Chollet P, Merrouche Y, Roche H, Fumoleau P, Kerbrat P, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:1564-71.
11. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. JClin Oncol 2005;23:1169-77.
12. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011;13:R97.
13. Karn T, Metzler D, Ruckhäberle E, Hanker L, Gätje R, Solbach C, et al. Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat 2010;120:567-79.
14. Warnat P, Eils R, Brors B. Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics 2005;6:265.
15. Glaab E, Garibaldi JM, Krasnogor N. Array Mining: a modular webapplication for microarray analysis combining ensemble and consensus methods with cross-study normalization. BMC Bioinformatics 2009;10:358.
16. Yu KD, Li S, Shao ZM. Different annual recurrence pattern between lumpectomy and mastectomy: implication for breast cancer surveillance after breast-conserving surgery. Oncologist 2011;16:1101-10.
17. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688-97.
18. Mansell J, Monypenny IJ, Skene AI, Abram P, Carpenter R, Gattuso JM, et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat 2009;117:91-8.
19. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001;98:31-6.
20. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
21. Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev 2008;17: 365-73.
22. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.
23. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.
24. Liao DJ, Dickson RB. Roles of androgens in the development, growth, and carcinogenesis of themammary gland. J Steroid Biochem Mol Biol 2002;80:175-89.
25. Loibl S, Muller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011;130: 477-87.
26. He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 2012;29:406-10.
27. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009;15:2472-8.
28. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 2005;65: 11259-64.
29. Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, Giguere V, et al. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene 2009;28:2634-42.
30. Chu IM, Michalowski AM, Hoenerhoff M, Szauter KM, Luger D, Sato M, et al. GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells. Oncogene 2012;31:2017-27.
31. Yan W, Cao QJ, Arenas RB, Bentley B, Shao R. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem 2010;285:14042-51.
32. Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, et al. Mutation of GATA3 in human breast tumors. Oncogene 2004;23:7669-78.
33. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
34. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, et al. Validation and clinical utility of a 70-geneprognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92.
35. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5.
36. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat 2011;126:407-20.